Free Trial
NASDAQ:MURA

Mural Oncology 5/14/2024 Earnings Report

Mural Oncology logo
$2.07 0.00 (0.00%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.08 +0.01 (+0.24%)
As of 09/5/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology EPS Results

Actual EPS
-$1.84
Consensus EPS
-$2.66
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A

Mural Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mural Oncology Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Mural Oncology's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Mural Oncology Earnings Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
See More Mural Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email.

About Mural Oncology

Mural Oncology (NASDAQ:MURA), Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents.

Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection.

Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.

View Mural Oncology Profile

More Earnings Resources from MarketBeat